Cagrilintide vs Semaglutide: What's the Difference?
Cagrilintide and semaglutide are two of the most discussed compounds in metabolic research right now — partly because they come from the same company (Novo Nordisk), and partly because they're being studied both separately and in combination, as the experimental therapy CagriSema. They work on completely different hormone systems, though, and understanding the difference matters for anyone following this research area. Here's how they compare.
The mechanisms: amylin vs GLP-1
Semaglutide is a GLP-1 receptor agonist — a synthetic version of the gut hormone GLP-1 (glucagon-like peptide-1). It enhances glucose-dependent insulin secretion, slows gastric emptying and acts on appetite centres in the brain. It's the most studied molecule in the entire class: approved as Ozempic (type 2 diabetes) and Wegovy (obesity), with years of real-world data behind it. In research settings, semaglutide is the reference compound for the GLP-1 pathway — the benchmark every new mechanism is measured against.
Cagrilintide comes at the same problem from a different direction entirely. It's a long-acting analogue of amylin — a hormone co-secreted with insulin by the pancreas — and it acts as a dual amylin and calcitonin receptor agonist. Amylin signalling contributes to satiety and gastric emptying through pathways that don't overlap completely with GLP-1, which is exactly why researchers find it interesting: it probes a parallel appetite-regulation system rather than a stronger version of the same one.
The shorthand: semaglutide works the GLP-1 pathway; cagrilintide works the amylin pathway.
What the clinical data shows
Semaglutide's pivotal obesity trials (the STEP programme) reported mean weight reduction of around 15–17% at the highest doses, results that transformed obesity medicine when they were published.
Cagrilintide has not been approved anywhere as a standalone medicine. It remains investigational, and the clearest picture of its potential comes from the REDEFINE Phase 3 programme, where it was tested head-to-head against semaglutide and placebo — and in combination with it. In REDEFINE 1 (published in the New England Journal of Medicine in June 2025, in adults with obesity without diabetes), the 68-week results were: CagriSema (the combination) 20.4% mean weight loss, semaglutide alone 14.9%, cagrilintide alone 11.5%, and placebo 3.0%. In participants who adhered to treatment for the full trial, the combination figure rose to 22.7%. REDEFINE 2, in participants with type 2 diabetes, showed a similar pattern: 13.7% for the combination versus 3.4% for placebo.
An honest caveat belongs in any summary of this data: Novo Nordisk had publicly aimed for 25% weight loss with the combination and fell short of it, and in the separate REDEFINE 4 head-to-head trial against tirzepatide, CagriSema did not demonstrate superiority. The combination is a real, clinically meaningful advance over either molecule alone — but the data supports precision, not hype.
Novo Nordisk submitted CagriSema to the US FDA in December 2025, with a decision expected in late 2026. Until regulators complete their review, both cagrilintide and the cagrilintide/semaglutide combination remain research-stage compounds.
Why researchers study them separately and together
The research logic is straightforward. Semaglutide alone tells you what the GLP-1 pathway can do. Cagrilintide alone tells you what the amylin pathway adds — and the REDEFINE data shows the answer is "a meaningful amount" (11.5% for cagrilintide alone is well above placebo). The combination tells you whether the two systems are complementary rather than redundant — and at roughly five percentage points of additional weight loss over semaglutide alone, the current evidence says they are. For laboratories studying appetite regulation, having each compound available separately is what makes the comparison possible at all.
Where Veritas Peptides fits in
Veritas Peptides stocks cagrilintide 10mg and the cagrilintide + semaglutide 10mg blend as research materials, each independently tested with a batch-specific, verifiable COA published in our COA library. Whether the research question is the amylin pathway in isolation or the combination effect that dominates the current literature, both compounds are available from UK stock.
The bottom line
Semaglutide is the approved, established GLP-1 benchmark — the molecule that defined the current era of metabolic research. Cagrilintide is its investigational counterpart on the amylin pathway — newer, less proven, but with strong Phase 3 evidence that the two systems add together rather than overlap. For researchers, they're complementary tools: the benchmark, and the molecule that tests what lies beyond it. And if you're following the triple-agonist story too, read our companion piece on retatrutide vs tirzepatide — the other great mechanism debate in this field.
All Veritas Peptides products are supplied strictly for research use only — laboratory and in-vitro research. They are not for human or animal consumption, diagnostic use, or any therapeutic application. Nothing in this article is medical advice or a recommendation of any kind.